Vascular endothelial growth factor (VEGF) is a potent endothelial cell mitogen, angiogenic factor and enhancer of vascular permeability. Expressed in the epithelial cells of the developing glomerulus and tubular epithelium, VEGF plays an important role in the development and maintenance of the early vasculature of the kidney. Here, we review the available literature regarding the expression and function of VEGF both in the developing and healthy adult kidney. Furthermore, we highlight how VEGF expression is altered in the diseased kidney and how this modulated expression may impact on and reflect underlying functional changes occurring during the disease process. As discussed, many controversial issues remain, particularly concerning the role of VEGF in the diseased kidney. That VEGF has been proposed as a potential future therapeutic target for the management of some renal diseases requires first that the precise role of VEGF in the normal kidney and various renal pathologies be further and more clearly defined.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000080686 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ICAM-1 expression is upregulated in the umbilical vein endothelial cells in acute chorioamnionitis with foetal inflammatory response.
Malays J Pathol
December 2024
Universiti Kebangsaan Malaysia, Faculty of Medicine, Department of Pathology, 56000 Kuala Lumpur, Malaysia.
Introduction: ICAM-1 is an adhesion molecule expressed on the endothelial cells and is involved in regulating leukocyte recruitment to the site of inflammation. Elevated ICAM-1 mRNA expression was found in the serum of mothers with chorioamnionitis. This study aimed to determine the expression of ICAM-1 in the placenta and umbilical cord of pregnancy with chorioamnionitis, and its association with adverse neonatal outcome.
View Article and Find Full Text PDFProtective role of Angiogenin in muscle regeneration in amyotrophic lateral sclerosis: Diagnostic and therapeutic implications.
Brain Pathol
December 2024
Laboratory of Neurobiology and Molecular Therapeutics, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.
Amyotrophic lateral sclerosis (ALS) is a fatal neuromuscular disease with no effective treatments, in part caused by variations in progression and the absence of biomarkers. Mice carrying the SOD1G93A transgene with different genetic backgrounds show variable disease rates, reflecting the diversity of patients. While extensive research has been done on the involvement of the central nervous system, the role of skeletal muscle remains underexplored.
View Article and Find Full Text PDFPrimary hepatic epithelioid hemangioendothelioma: a case report.
J Int Med Res
December 2024
Department of Hepatobiliary Surgery, Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine, Hangzhou, China.
Epithelioid hemangioendothelioma is a low-grade malignant tumor of vascular origin. The rarity of hepatic epithelioid hemangioendothelioma (HEHE) makes the diagnosis and treatment of this entity challenging. We report a case of a 69-year-old female patient who suffered from HEHE and complained of abdominal distension pain with dizziness and appetite loss for more than half a month.
View Article and Find Full Text PDFOutliers of Treatment Frequency in Retinal Vein Occlusion: 24-Month Comparative Analysis of Fight Retinal Blindness! Practitioners.
Clin Exp Ophthalmol
December 2024
The Save Sight Institute, Sydney Medical School, the University of Sydney, Sydney, New South Wales, Australia.
Background: We aimed to describe a 2-year outcome of eyes managed by practitioners benchmarked using a funnel plot by their frequency of treatment using vascular endothelial growth factor (VEGF) inhibitors for naive retinal vein occlusion (RVO).
Methods: A multicentre, international, observational study of 29 doctors in 12 countries managing 1110 eyes with RVO commencing VEGF inhibitors between 1 January 2012-2022 tracked in the Fight Retinal Blindness! registry.
Results: We identified 3 outlying 'intensive' practitioners (managing 350/1110 eyes [32%]), 22 'typical' practitioners (604/1110, [54%]) and 4 outlying 'relaxed' practitioners (156/1110, [14%]) with respective 24-month outcomes in Branch and Central RVO including the primary outcome, mean adjusted change in visual acuity (VA) in BRVO: +16.
[Activation of endogenous mechanisms of sanogenesis in cognitive impairment in cerebral small vessel disease].
Zh Nevrol Psikhiatr Im S S Korsakova
December 2024
Kazan (Volga region) Federal University, Kazan, Russia.
Cerebrovascular diseases themselves are the second most common cause of cognitive impairment (dementia). In addition, cerebral small vessel disease (CSVD) makes a significant contribution to the clinical picture of neurodegenerative diseases. Since there are currently no pharmacological treatments for CSVD, a promising method is the activation of the endogenous mechanisms of sanogenesis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!